JP2010511721A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511721A5
JP2010511721A5 JP2009540401A JP2009540401A JP2010511721A5 JP 2010511721 A5 JP2010511721 A5 JP 2010511721A5 JP 2009540401 A JP2009540401 A JP 2009540401A JP 2009540401 A JP2009540401 A JP 2009540401A JP 2010511721 A5 JP2010511721 A5 JP 2010511721A5
Authority
JP
Japan
Prior art keywords
independently
compound
heteroaryl
alkyl
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009540401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511721A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/086220 external-priority patent/WO2008070599A1/en
Publication of JP2010511721A publication Critical patent/JP2010511721A/ja
Publication of JP2010511721A5 publication Critical patent/JP2010511721A5/ja
Withdrawn legal-status Critical Current

Links

JP2009540401A 2006-12-05 2007-12-03 インダゾール化合物 Withdrawn JP2010511721A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87304106P 2006-12-05 2006-12-05
PCT/US2007/086220 WO2008070599A1 (en) 2006-12-05 2007-12-03 Indazole compounds

Publications (2)

Publication Number Publication Date
JP2010511721A JP2010511721A (ja) 2010-04-15
JP2010511721A5 true JP2010511721A5 (enExample) 2011-01-27

Family

ID=39492604

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009540401A Withdrawn JP2010511721A (ja) 2006-12-05 2007-12-03 インダゾール化合物

Country Status (9)

Country Link
US (1) US7825261B2 (enExample)
EP (1) EP2091329A4 (enExample)
JP (1) JP2010511721A (enExample)
KR (1) KR20090127867A (enExample)
CN (1) CN101616587A (enExample)
AU (1) AU2007329480A1 (enExample)
CA (1) CA2671543A1 (enExample)
TW (1) TWI433672B (enExample)
WO (1) WO2008070599A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697685B2 (en) 2008-11-20 2014-04-15 Glaxosmithkline Llc Chemical compounds
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
KR101552760B1 (ko) 2009-12-18 2015-09-11 미쓰비시 타나베 파마 코퍼레이션 신규 항혈소판약
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
JP6370887B2 (ja) 2013-05-23 2018-08-08 バイエル・ファルマ・アクティエンゲゼルシャフト オンデマンド避妊のための医薬組成物およびその使用、ならびにこの医薬組成物の適用体制
CN105358544A (zh) 2013-07-09 2016-02-24 武田药品工业株式会社 杂环化合物
KR101713303B1 (ko) 2015-12-24 2017-03-07 강원대학교산학협력단 2h-인다졸 유도체의 제조방법
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
MX2020008949A (es) 2018-02-27 2021-01-08 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
GB201806320D0 (en) 2018-04-18 2018-05-30 Cellcentric Ltd Process
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20220356163A1 (en) * 2019-10-01 2022-11-10 Memorial Sloan Kettering Cancer Center SMALL MOLECULE INHIBITORS OF Id PROTEINS
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ334213A (en) * 1996-09-04 2000-08-25 Pfizer Indazole derivatives as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) for treating asthma, arthritis, bronchitis, CNS disorders
JP2002533391A (ja) * 1998-12-23 2002-10-08 エヌピーエス アレリックス コーポレーション 偏頭痛の治療のためのインドールおよびインドリジジン誘導体
US7141581B2 (en) * 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
WO2003020698A2 (en) * 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
JP2006522794A (ja) * 2003-04-10 2006-10-05 ファイザー株式会社 Nr2b受容体拮抗物質としての二環系化合物
EP1631568A1 (en) * 2003-04-18 2006-03-08 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
JP2007532658A (ja) * 2004-04-16 2007-11-15 スミスクライン ビーチャム コーポレーション がんの治療方法
CA2584317A1 (en) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AU2005322338B2 (en) * 2004-12-27 2011-06-09 Alcon, Inc. Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
US8431695B2 (en) * 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases

Similar Documents

Publication Publication Date Title
JP2010511721A5 (enExample)
JP2009529540A5 (enExample)
JP2012508252A5 (enExample)
JP2011522789A5 (enExample)
JP2011037841A5 (enExample)
JP2012515776A5 (enExample)
JP2013512915A5 (enExample)
JP2011513410A5 (enExample)
JP2010527913A5 (enExample)
JP2008510828A5 (enExample)
JP2009504764A5 (enExample)
JP2007522220A5 (enExample)
JP2009535358A5 (enExample)
JP2008510770A5 (enExample)
JP2010504908A5 (enExample)
JP2010536766A5 (enExample)
JP2006505543A5 (enExample)
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
JP2012092103A5 (enExample)
JP2009536221A5 (enExample)
JP2010501478A5 (enExample)
JP2009538336A5 (enExample)
JP2016507575A5 (enExample)
JP2014526533A5 (enExample)
JP2020128426A5 (enExample)